11.43
price down icon0.57%   -0.021
 
loading
Precedente Chiudi:
$11.45
Aprire:
$11.53
Volume 24 ore:
47,976
Relative Volume:
0.08
Capitalizzazione di mercato:
$483.18M
Reddito:
$82.71M
Utile/perdita netta:
$-102.24M
Rapporto P/E:
-2.4421
EPS:
-4.68
Flusso di cassa netto:
$-76.57M
1 W Prestazione:
-4.01%
1M Prestazione:
-9.07%
6M Prestazione:
-14.20%
1 anno Prestazione:
-10.14%
Intervallo 1D:
Value
$11.31
$11.67
Intervallo di 1 settimana:
Value
$10.62
$11.95
Portata 52W:
Value
$10.60
$20.70

Urogen Pharma Ltd Stock (URGN) Company Profile

Name
Nome
Urogen Pharma Ltd
Name
Telefono
972 9 770 7601
Name
Indirizzo
9 HA'TA'ASIYA ST, RA'ANANA
Name
Dipendente
217
Name
Cinguettio
@UroGenPharma
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
URGN's Discussions on Twitter

Confronta URGN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
URGN 11.38 483.18M 82.71M -102.24M -76.57M -4.68
VRTX 446.64 115.74B 10.63B -479.80M -1.35B 13.33
REGN 739.77 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 588.98 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.89 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.94 24.49B 3.30B -501.07M 1.03B 11.54

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-02-08 Downgrade Jefferies Buy → Hold
2022-04-27 Iniziato Berenberg Buy
2020-04-16 Reiterato H.C. Wainwright Buy
2020-04-13 Reiterato H.C. Wainwright Buy
2020-01-09 Iniziato National Securities Neutral
2019-05-30 Iniziato JP Morgan Neutral
2019-05-29 Iniziato Goldman Neutral
2019-01-29 Iniziato H.C. Wainwright Buy
2018-11-08 Ripresa Jefferies Buy
2018-04-04 Aggiornamento Raymond James Mkt Perform → Outperform
2018-01-02 Iniziato Ladenburg Thalmann Buy
2017-11-15 Reiterato Oppenheimer Outperform
2017-11-15 Downgrade Raymond James Outperform → Mkt Perform
Mostra tutto

Urogen Pharma Ltd Borsa (URGN) Ultime notizie

pulisher
Nov 18, 2024

Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load? - Simply Wall St

Nov 18, 2024
pulisher
Nov 15, 2024

RA Capital Management, L.P. Increases Stake in UroGen Pharma Ltd - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Analysis of GREAT POINT PARTNERS LLC's Recent Transaction in Uro - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Analysis of COWEN AND COMPANY, LLC's Strategic Reduction in UroG - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

RTW INVESTMENTS, LP Acquires Significant Stake in UroGen Pharma Ltd - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

UroGen Pharma: Choice Based On Near-Term High-Value PDUFA - Seeking Alpha

Nov 13, 2024
pulisher
Nov 13, 2024

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business HighlightsURGN Pharmaceuticals, a leading biotech company focused on urothelial and specialty cancers, disclosed its latest financial outcomes for the third quarter ended Septemb - Defense World

Nov 13, 2024
pulisher
Nov 11, 2024

UroGen Pharma Reports Q3 Results and Drug Progress - TipRanks

Nov 11, 2024
pulisher
Nov 11, 2024

HC Wainwright Forecasts Stronger Earnings for UroGen Pharma - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024
pulisher
Nov 07, 2024

UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance

Nov 07, 2024
pulisher
Nov 06, 2024

Morgan Stanley's Strategic Acquisition of UroGen Pharma Shares - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 - BioSpace

Nov 06, 2024
pulisher
Nov 06, 2024

Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

UroGen Pharma Ltd (URGN) Q3 2024 Earnings: EPS of ($0.55) and Re - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

UroGen Pharma Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024
pulisher
Nov 06, 2024

UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada

Nov 06, 2024
pulisher
Nov 05, 2024

URGNUroGen Pharma Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference - Business Wire

Nov 05, 2024
pulisher
Nov 04, 2024

(URGN) Investment Analysis - Stock Traders Daily

Nov 04, 2024
pulisher
Nov 02, 2024

Rice Hall James & Associates LLC Grows Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat

Nov 02, 2024
pulisher
Oct 31, 2024

UroGen Pharma (URGN) to Release Quarterly Earnings on Wednesday - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 - BioSpace

Oct 30, 2024
pulisher
Oct 28, 2024

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC - Business Wire

Oct 28, 2024
pulisher
Oct 25, 2024

(URGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 25, 2024
pulisher
Oct 21, 2024

UroGen started at buy by EF Hutton, RTGel technology cited - MSN

Oct 21, 2024
pulisher
Oct 19, 2024

Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years - Yahoo Finance

Oct 19, 2024
pulisher
Oct 17, 2024

UroGen Pharma maintains Outperform stock rating on new drug application By Investing.com - Investing.com Australia

Oct 17, 2024
pulisher
Oct 17, 2024

FDA accepts UroGen's NDA for bladder cancer treatment - Investing.com India

Oct 17, 2024
pulisher
Oct 16, 2024

When Would Be The Best Time To Buy UroGen Pharma Ltd (NASDAQ: URGN) Stock? - Stocks Register

Oct 16, 2024
pulisher
Oct 16, 2024

URGN’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle

Oct 16, 2024
pulisher
Oct 16, 2024

UroGen Pharma maintains Outperform stock rating on new drug application - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

UroGen Pharma Ltd (URGN) looking to reclaim success with recent performance - SETE News

Oct 16, 2024
pulisher
Oct 16, 2024

UroGen Pharma (NASDAQ:URGN) Receives "Outperform" Rating from Oppenheimer - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Wesbanco Bank Inc. Buys Shares of 74,400 UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

FDA accepts UroGen’s UGN-102 NDA for bladder cancer treatment - Pharmaceutical Technology

Oct 16, 2024
pulisher
Oct 15, 2024

UroGen Pharma Says FDA Accepts NDA for UGN-102 - Marketscreener.com

Oct 15, 2024
pulisher
Oct 15, 2024

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 - The Bakersfield Californian

Oct 15, 2024
pulisher
Oct 15, 2024

UroGen Pharma Ltd (URGN) is a good investment, but the stock may be undervalued - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

UroGen Pharma's (URGN) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

UroGen Pharma (NASDAQ:URGN) Upgraded to "Strong-Buy" by EF Hutton Acquisition Co. I - MarketBeat

Oct 15, 2024
pulisher
Oct 14, 2024

EF Hutton initiates UroGen Pharma shares with Buy rating By Investing.com - Investing.com South Africa

Oct 14, 2024
pulisher
Oct 14, 2024

EF Hutton Initiates Coverage of UroGen Pharma (URGN) with Buy Recommendation - MSN

Oct 14, 2024
pulisher
Oct 11, 2024

UroGen Pharma Ltd [URGN] Chief Medical Officer makes an insider sale of 859 shares worth 11,236. - Knox Daily

Oct 11, 2024
pulisher
Oct 10, 2024

Healthy Upside Potential: UroGen Pharma Ltd (URGN) - SETE News

Oct 10, 2024
pulisher
Oct 09, 2024

UroGen Pharma announces executive changes By Investing.com - Investing.com South Africa

Oct 09, 2024
pulisher
Oct 09, 2024

UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

UroGen Pharma Announces Departure of CFO and Appointment of New CFO - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

UroGen Appoints Chris Degnan as Chief Financial Officer - citybiz

Oct 09, 2024
pulisher
Oct 09, 2024

UroGen Pharma announces executive changes - Investing.com

Oct 09, 2024

Urogen Pharma Ltd Azioni (URGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):